Replies to post #404837 on Amarin Corp Plc (AMRN)

[Birdrockboy]

Hoping that Kaiser ran patients for two years……. All will be revealed soon.

[Tatsumaki]

And when Mitigate doesn't fix all of Amarin's issues and make V suddenly sell itself, what's the next study we're waiting for?

[Laurent Maldague]

Kiwi, I am also keenly interested in the MITIGATE results as you know. I don't know what to make of the radio silence. I do hope Dr. Ambrosy/Bhatt and Amarin scientists have pivoted to using this trial to get CVD data, because I think at this point that has become more important than the purely COVID portion.

What's been on my mind about MITIGATE is, should they stop the trial Feb 28th 2023, or should they run it for one more year? My feeling is that adding an additional year should make strong CVD results a near certainty, whereas stopping the trial today feels like a gamble. Obviously only the investigators are privy to the aggregate event rate and discontinuation rates, and only they can make the appropriate call. If they did already end the trial, we should see an update on clinical trials .gov within the next two months or so I would assume (and perhaps a late breaker appearance at ESC Congress 2023 in the summer.)

[ziploc_1]

KIWI ...Could Kaiser have submitted the Mitigate study results to the ACC in N.O. on march 4 through 6 as a late breaking study?